135 related articles for article (PubMed ID: 18349823)
1. Optimum management of glucocorticoid-treated patients.
Trikudanathan S; McMahon GT
Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):262-71. PubMed ID: 18349823
[TBL] [Abstract][Full Text] [Related]
2. An overview of the adverse reactions to adrenal corticosteroids.
Frauman AG
Adverse Drug React Toxicol Rev; 1996 Nov; 15(4):203-6. PubMed ID: 9113247
[TBL] [Abstract][Full Text] [Related]
3. Pulse glucocorticoid therapy. The 'big shot' revisited.
Roujeau JC
Arch Dermatol; 1996 Dec; 132(12):1499-502. PubMed ID: 8961881
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic issues in oral glucocorticoid use.
Bello CE; Garrett SD
Lippincotts Prim Care Pract; 1999; 3(3):333-41; quiz 342-4. PubMed ID: 10711134
[TBL] [Abstract][Full Text] [Related]
5. Use of glucocorticoids and risk of infections.
Cutolo M; Seriolo B; Pizzorni C; Secchi ME; Soldano S; Paolino S; Montagna P; Sulli A
Autoimmun Rev; 2008 Dec; 8(2):153-5. PubMed ID: 18703175
[TBL] [Abstract][Full Text] [Related]
6. [Clinical studies on glucocorticoid-induced osteoporosis].
Tanaka I; Oshima H
Nihon Rinsho Meneki Gakkai Kaishi; 2001 Aug; 24(4):142-151. PubMed ID: 16646164
[No Abstract] [Full Text] [Related]
7. [Glucocorticoid].
Sato Y; Munakata Y
Nihon Rinsho; 2012 Aug; 70 Suppl 6():172-7. PubMed ID: 23156504
[No Abstract] [Full Text] [Related]
8. [Adverse effects in short-term steroid therapy. Which adverse effects can be expected during daily administration of 20-40 mg prednisolone for a period 1-3 weeks?].
Jarlbaek L; Gram LF; Arnberg A
Ugeskr Laeger; 2000 Jan; 162(4):528-9. PubMed ID: 10697459
[No Abstract] [Full Text] [Related]
9. Primary and secondary prophylaxis to the use of inhaled glucocorticoid in primary health care.
Nielsen BR; Jørgensen NR; Schwarz P
J Asthma; 2008 Aug; 45(6):519-22. PubMed ID: 18612907
[TBL] [Abstract][Full Text] [Related]
10. Genomic and nongenomic effects of glucocorticoids.
Stahn C; Buttgereit F
Nat Clin Pract Rheumatol; 2008 Oct; 4(10):525-33. PubMed ID: 18762788
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of glucocorticoid-induced osteoporosis.
Civitelli R; Ziambaras K
J Endocrinol Invest; 2008 Jul; 31(7 Suppl):2-6. PubMed ID: 18791344
[TBL] [Abstract][Full Text] [Related]
12. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.
García-Gómez C; Nolla JM; Valverde J; Narváez J; Corbella E; Pintó X
Eur J Clin Invest; 2008 Sep; 38(9):686-92. PubMed ID: 18837746
[TBL] [Abstract][Full Text] [Related]
13. [New glucocorticoids are more selective. Current knowledge can eliminate serious adverse effects].
Nilsson S; Gustafsson JA
Lakartidningen; 1997 Jun; 94(26-27):2465-71. PubMed ID: 9235445
[TBL] [Abstract][Full Text] [Related]
14. Population-based assessment of adverse events associated with long-term glucocorticoid use.
Curtis JR; Westfall AO; Allison J; Bijlsma JW; Freeman A; George V; Kovac SH; Spettell CM; Saag KG
Arthritis Rheum; 2006 Jun; 55(3):420-6. PubMed ID: 16739208
[TBL] [Abstract][Full Text] [Related]
15. Dose-related patterns of glucocorticoid-induced side effects.
Huscher D; Thiele K; Gromnica-Ihle E; Hein G; Demary W; Dreher R; Zink A; Buttgereit F
Ann Rheum Dis; 2009 Jul; 68(7):1119-24. PubMed ID: 18684744
[TBL] [Abstract][Full Text] [Related]
16. Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know.
Dixon WG; Bansback N
Ann Rheum Dis; 2012 Nov; 71(11):1761-4. PubMed ID: 22851467
[TBL] [Abstract][Full Text] [Related]
17. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
18. Will we ever have better glucocorticoids?
Buttgereit F; Bijlsma JWJ; Strehl C
Clin Immunol; 2018 Jan; 186():64-66. PubMed ID: 28757452
[TBL] [Abstract][Full Text] [Related]
19. [Benefits and risks of glucocorticoid therapy for the treatment of rheumatoid arthritis and management of glucocorticoid-induced osteoporosis].
Suzuki Y; Wakabayashi T; Saito E; Yamada C; Suwa A
Clin Calcium; 2009 Mar; 19(3):404-15. PubMed ID: 19252251
[TBL] [Abstract][Full Text] [Related]
20. The epidemiology of glucocorticoid-associated adverse events.
McDonough AK; Curtis JR; Saag KG
Curr Opin Rheumatol; 2008 Mar; 20(2):131-7. PubMed ID: 18349741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
